R&D Improving treatment for high-risk cataract surgery Cataracts rank among the most prevalent age-related ailments.
Patients Developing bold medicines to preserve vision and transform t... My training as a clinical ophthalmologist and retinal surgeon led me to a career dedicated to developing better therapies for people suffering from debilitating eye diseases and the many co
Partner Content Partner Content Industry news with an exclusive interview by from Aerie Phar... Ophthalmic Drugs
Partner Content Partner Content Europe’s Leading Ophthalmic Conference is Just 1 week away Ophthalmic Drugs
Partner Content Partner Content SMi’s Europe’s Leading Ophthalmic Conference is only 2 weeks... Ophthalmic Drugs
Partner Content Partner Content SMi’s Europe’s Leading Ophthalmic Conference is only 3 weeks... Europe's Leading Ophthalmic Conference
News Zymeworks cuts deal to buy Theravance for $929m in cash Zymeworks has reached a deal to buy Theravance, claiming rights to COPD therapy Yupelri, sold by Viatris, which made $267m last year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
